Hybridan Small Cap Feast: 12/04/2024

* A corporate client of Hybridan LLP

** Arranged by type of listing and date of announcement

*** Alphabetically arranged

**** Potential means Intention to Float (ITF) has been announced

Dish of the day

Admissions:   

Delistings: 

What’s baking in the oven? **

Potential****  Initial Public Offerings:

Reverse Takeovers:

Change of Market:

TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated proposition as a value alternative to full price specialist retailers. The Company is listed on the premium segment of the Main market of the London Stock Exchange. The Company has announced its intention to change to the AIM  market on 3 May 2024. Currently the market capitalisation of TheWorks is £16m.

 Banquet Buffet***

CleanTech Lithium  12.75p £18.5m (CTL.L) Follow | CTL

The Board of Directors of the exploration and development company advancing lithium projects in Chile, has accepted the resignation from Mr Aldo Boitano as CEO and director of the Company with immediate effect. Executive Chairman Steve Kesler will serve as CEO on an interim basis. This will ensure no impact to the Company's operations including ongoing activities at CTL's most advanced development project, Laguna Verde. As Executive Chairman, Steve has been working closely with Mr Boitano and is well placed to ensure ongoing continuity and progress.

Cykel AI  9.25p £19.0m (AQSE: CYK) Follow | CYK

The software business developing advanced artificial intelligence (AI) products, jointly announces with Mustang Energy PLC that the Takeover Panel has consented to an extension to the Deadline until 5.00 p.m. (London time) on 10 May 2024. The Deadline may be further extended with the consent of the Panel, at Cykel's request, in accordance with Rule 2.6(c) of the Code. On 19 January 2024, Mustang Energy and Cykel AI announced that they had entered into a non-binding heads of terms for Mustang to acquire the entire issued share capital of Cykel. Discussions remain ongoing and the draft prospectus for the issue of the new Mustang shares to Cykel shareholders remains in the review process of the Financial Conduct Authority.

Directa Plus 20.5p £13.5m (DCTA.L) Follow | DCTA

The producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets announces the installation of GiPave® at the Imola Circuit ahead of the upcoming Emilia-Romagna Grand Prix in May 2024 as part of the Formula 1 World Championship, making it the first circuit to feature green, sustainable and high-tech asphalt utilising graphene and recycled plastics. GiPave® was developed by Iterchimica and resulted from a multi-year research programme conducted in collaboration with G.Eco of the A2A Group, the University of Milano-Bicocca, and Directa Plus.

Frontier IP  42.5p £23.9m (FIPP.L) Follow | FIPP

The Company in commercialising intellectual property announces the appointment of Jo Stent as Chief Financial Officer with effect from 22 April 2024. Jo is a chartered accountant, having qualified at Ernst & Young, and brings nearly 30 years' experience in senior financial roles across a broad range of sectors and geographies. Jo was most recently CFO at AIM quoted Argentex Group Plc, provider of bespoke currency risk management and payment solutions, from February 2021 to January 2024. She was previously Chief Financial Officer of the European Tour and Ryder Cup Europe. She is also a former CFO of Vodafone Americas and previously held senior positions at Telus Communications and Deloitte.

Marula Mining 9p £15.6m (AQSE: MARU) Follow | MARU

The African focused mining and development company, announces that following the completion of the initial exploration program, and the assay results confirming high-grade, coarse flake and broad graphite mineralisation, at the Nyorinyori Graphite Project (Nyorinyori) and the NyoriGreen Graphite Project (NyoriGreen) (together the "Projects) in Tanzania, the Company has issued its share based consideration to Takela Mining Tanzania Limited ("TMT") and NyoriGreen Mining Limited (NML). As announced on 17 February 2023, upon the completion of the initial exploration program, Marula is required to complete a share-based payment of £100k to TMT through the issue of 799,361 new ordinary shares at a price of 12.51p, which is based on the 30-day volume-weighted average price (VWAP). The Company will also complete a share-based payment of £250k to NML through the issue of 1,998,401 new ordinary shares at the VWAP of 12.51p, as announced on 28 September 2023. In aggregate 2,797,762 new ordinary shares have been issued at a price of 12.51p per share (the Milestone Shares). 

Huddled Group 2.75p £8.8m (HUD.L) Follow | HUD

The Group focused on building a portfolio of e-commerce brands announces the acquisition of online retailer Food Circle Supermarket Ltd for total consideration of up to £300,000. The Acquisition comprises the entire stock, intellectual property and website and other social channels of Food Circle Supermarket. Food Circle is complementary to the Group's Discount Dragon business and is the next step in the Group's strategy to build a portfolio of e-commerce brands. Aligned with Discount Dragon, Food Circle reduces food waste and surplus food through the sale of discounted and short-dated stock. Food Circle delivered unaudited revenue of £1.4m and a small net loss of £46k for the year ended 31 December 2023.   

Oxford Cannabinoid Technologies * 0.335p £3.6m (OCT.L) Follow | OCT

The clinical stage biopharmaceutical company focused on the development and commercialisation of innovative cannabinoid medicines announced yesterday that, through its subsidiary, OCT Victoria Pty Ltd, it has entered into agreement with iNGENū CRO Pty Ltd, to conduct a Phase I randomised, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability and pharmacokinetics of OCT130401. iNGENū is an Australia-based, globally focused contract research organisation possessing extensive experience working in the cannabinoid pharmaceutical drug development and clinical research industry. OCT130401 is a combination of synthetic phytocannabinoids (pCBs) and a medical device for the effective, safe, and non-addictive treatment of chronic and severe pain conditions. The initial target for OCT130401 is trigeminal neuralgia (TN), a chronic pain condition that causes an excruciating, stabbing, electric shock-like facial pain.

Premier African Minerals 0.185p £51.5m (PREM.L) Follow | PREM

The Company announces that following strong institutional interest following the funding announced on 11 April 2024, the Company has agreed to accept a further subscription of 588,235,294 new ordinary shares to raise approximately £1m before expenses at the same issue price of 0.17p per new ordinary share, primarily for the Zulu Lithium and Tantalum Project. Application will be made for the Subscription Shares to be admitted to trading on AIM and admission is expected to take place on or around 19 April 2024.

R&Q Insurance 3.005p £11.2m (RQIH.L) Follow | RQIH

The global non-life specialty insurance company announced that it has reached an agreement for Obra Capital, Inc. (together with its affiliates and funds/clients advised by Obra Capital Management, LLC, collectively "Obra") to acquire all of the interests held by R&Q and its affiliates in the Joint Venture between Obra and R&Q, Sag Main Holdings LLC (the JV). Under the terms of the transaction agreements with Obra, R&Q Solutions LLC and R&Q Re (Bermuda) Ltd. will transfer their collective 49% interest in the JV to Obra. The fee income received by R&Q in 2023 was $7m. As consideration, R&Q will receive from Obra cash of $27m alongside the transfer and delivery of $3m of preference shares held by Obra in Randall & Quilter PS Holdings Inc. Meanwhile, based on preliminary and unaudited information R&Q anticipates that it will realise a significant pre-tax loss for the year driven by the adverse development in Legacy and a material increase in corporate costs in relation to the Sale of Accredited.

TERN 2.55p £10.4m (TERN.L) Follow | TERN

The investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, announces that it has raised £420,000, before expenses, through a placing of 17,500,000 new ordinary shares at a price of 2.4p per new Ordinary Share. The Issue Price represents a discount of approximately 30.4% to the mid-market closing price of 3.45p per Ordinary Share on 11 April 2024. The net proceeds will be used to provide the Company with funds to invest in Wyld Networks, through the exercise of warrants held by the Company, and to invest further in one or more of Tern's portfolio companies and for general corporate purposes. 

 Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II       Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.